Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (January 2022)
13 slides from Harrow's investor presentation, Jan 10, 2022
Slide 1: Corporate Presentation | January 2022
HEALTH INC. Corporate Presentation | January 2022
Slide 2: Safe Harbor
Safe Harbor This presentation contains express “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying a
Slide 3: Harrow Health, Inc.
Harrow Health, Inc. » The only U.S. ophthalmic-focused pharmaceutical company to provide both branded FDA-approved products and cGMP compounded formulations, serving more than 10,000 doctors, hospitals and ASCs. > 53% revenue growth rate (2021 vs. 2020 3Q YTD). > 776% adjusted EBITDA growth (2021 vs
Slide 4: Harrow’s ImprimisRx Platform
Harrow’s ImprimisRx Platform >» Avertically integrated FDA-registered ophthalmic pharmaceutical brand, consisting of integrated national sales and customer service teams, automated cGMP drug compounding facilities, and an efficient, scalable, and tech-enabled national distribution platform, includin
Slide 5: Harrow’s Simple Approach
d Harrow’s Simple Approach MD Office, Hospital or ASC Nationwide Production and Dispensing at Harrow-Owned Facilities MD/Hospital Prescription Patient » Cash-pay focused; now integrating high-value reimbursable FDA-approved products. > We seek to disintermediate all “middlemen” in the traditional va
Slide 6: YTD Record Revenues, Gross Margin and Assets
YTD Record Revenues, Gross Margin and Assets (Revenues and Assets in Thousands) $102,801 51% 46% $59,085 $57,474 $49,451 $48,871 34% $27,247 $26,774 23,917 $19,942 $14,131 $10,242 $9,716 ji $1,660 2014 2015 2016 2017 2018 2019 2020 3Q YTD 2021 HI Consolidated Revenues M5 Assets cross Margin ig eta a
Slide 7: Adjusted E(L)BITDA Growth and Expense Control
Adjusted E(L)BITDA Growth and Expense Control (Dollars in Thousands) $14,900 $(7,000) $(10,000) $(10,000) 2015 2016 2017 2018 2019 2020 3Q YTD 2021 4 HARROW HE Adjusted E(L)BITDA 1) Operating Expense as a % of Revenue
Slide 8: Crossing the Bridge
Crossing the Bridge Becoming the Next Great U.S. Ophthalmic Pharmaceutical A Re a a A A Company cd HARROW HEALTH ING) >» Continued organic revenue growth. » Developing late-stage product candidates. > Forming new commercial partnerships. > Selling recently acquired FDA-approved drugs. 4 HARROW HEALT
Slide 9: Adding High-Value FDA-Approved Products
Adding High-Value FDA-Approved Products > In 2021, we raised $85 million (sale of $10 million in Eton stock and $75 million in unsecured senior notes): > Purchased U.S. and Canada rights to AMP-100 (NDA on file with FDA): > If approved, commercial focus will be ophthalmic procedures requiring the ey
Slide 10: Value Inflection Timing
Value Inflection Timing Submitted NDA for Expected Fortisite™ AMP-100 commercial launch Expected AMP-100 FDA approval Revenues from Newly acquired ena 2 Expected AMP-100 branded portfolio Guess winciearce) commercial launch (IOPIDINE®; MAXITROL®; MOXEZA®) Expected meeting with FDA to discuss MAQ-100
Slide 11: Royalty Pipeline
Royalty Pipeline >» Surface Ophthalmics and Melt Pharmaceuticals were founded as Harrow Health subsidiaries. >» Surface was carved out in May 2018 and Melt was carved out in February 2019. » Harrow owns: > Equity in Surface and Melt (20% and 46%, respectively); >» $13.5M senior secured note and ROFR
Slide 12: Harrow Health, Inc.
d Harrow Health, Inc. > 2022 expectations: Growing revenues, stable gross margins and OpEx/revenue ratio. > Completed seven accretive/consequential deals during last 18 months. >» Revenues expected to more than double within a few years of product launch, with an improving gross margin profile, when
Slide 13: Woodmont Bivd., Ste
102 Woodmont Bivd., Ste 610 Nashville, Tennessee 37205 www.Harrowlnc.com Jamie Webb | E A En | | N Cc. Director of Communications and Investor Relations jwebb@harrowinc.com Direct: 615-733-4737